Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Selman, A. Pardo (2014)
Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model.American journal of respiratory and critical care medicine, 189 10
Thabut (2003)
Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosisJ Thorac Cardiovasc Surg, 126
M. Seibold, A. Wise, M. Speer, M. Steele, K. Brown, J. Loyd, T. Fingerlin, Weiming Zhang, G. Gudmundsson, S. Groshong, C. Evans, S. Garantziotis, K. Adler, B. Dickey, R. Bois, Ivana Yang, A. Herron, D. Kervitsky, Janet Talbert, C. Markin, Joungjoa Park, A. Crews, S. Slifer, S. Auerbach, Michelle Roy, Jia Lin, Corinne Hennessy, M. Schwarz, D. Schwartz (2011)
A common MUC5B promoter polymorphism and pulmonary fibrosis.The New England journal of medicine, 364 16
K. Baumgartner, J. Samet, D. Coultas, C. Stidley, W. Hunt, T. Colby, J. Waldron (2000)
Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers.American journal of epidemiology, 152 4
D. Chambers, D. Enever, N. Ilić, L. Sparks, K. Whitelaw, J. Ayres, S. Yerkovich, D. Khalil, Kerry Atkinson, P. Hopkins (2014)
A phase 1b study of placenta‐derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosisRespirology, 19
John Hutchinson, A. Fogarty, R. Hubbard, T. McKeever (2015)
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic reviewEuropean Respiratory Journal, 46
T. Ogura, H. Taniguchi, A. Azuma, Y. Inoue, Y. Kondoh, Y. Hasegawa, M. Bando, S. Abe, Y. Mochizuki, K. Chida, M. Klüglich, Tsuyoshi Fujimoto, Kotaro Okazaki, Y. Tadayasu, W. Sakamoto, Y. Sugiyama (2014)
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 45
K. Oda, K. Yatera, Y. Fujino, H. Ishimoto, Hiroyuki Nakao, Tetsuya Hanaka, Takaaki Ogoshi, T. Kido, K. Fushimi, S. Matsuda, H. Mukae (2016)
Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in JapanBMC Pulmonary Medicine, 16
(2002)
The Journal of Thoracic and Cardiovascular Surgery is the official publication of the American Association for Thoracic Surgery and the Western Thoracic Surgical Association. Copyright © 2003 American Association for Thoracic Surgery Downloaded from
M. Funke, T. Geiser (2015)
Idiopathic pulmonary fibrosis: the turning point is now!Swiss medical weekly, 145
G. Raghu, H. Collard, J. Egan, F. Martinez, J. Behr, K. Brown, T. Colby, Jean-Franc, ois Cordier, K. Flaherty, J. Lasky, D. Lynch, J. Ryu, J. Swigris, A. Wells, J. Ancochea, D. Bouros, Carlos Carvalho, U. Costabel, M. Ebina, D. Hansell, T. Johkoh, D. Kim, T. King, Y. Kondoh, J. Myers, N. Müller, A. Nicholson, L. Richeldi, M. Selman, R. Dudden, Barbara Griss, Shandra Protzko, H. Schünemann (2011)
American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management
R. Borie, A. Justet, G. Beltramo, E. Manali, P. Pradere, P. Spagnolo, B. Crestani (2016)
Pharmacological management of IPFRespirology, 21
T. King, W. Bradford, S. Castro-Bernardini, E. Fagan, I. Glaspole, M. Glassberg, E. Gorina, P. Hopkins, D. Kardatzke, L. Lancaster, D. Lederer, S. Nathan, C. Pereira, S. Sahn, R. Sussman, J. Swigris, P. Noble (2014)
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.The New England journal of medicine, 370 22
M. Inomata, Y. Nishioka, A. Azuma (2015)
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosisCore Evidence, 10
Funke (2015)
Idiopathic pulmonary fibrosis: the turning point is now!Swiss Med Wkly, 145
G. Raghu, B. Rochwerg, Y. Zhang, C. Garcia, A. Azuma, J. Behr, J. Brożek, H. Collard, W. Cunningham, S. Homma, T. Johkoh, F. Martinez, J. Myers, Shandra Protzko, L. Richeldi, D. Rind, M. Selman, A. Theodore, A. Wells, H. Hoogsteden, H. Schünemann (2015)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.American journal of respiratory and critical care medicine, 192 2
M. Donahoe, V. Valentine, N. Chien, K. Gibson, J. Raval, M. Saul, Jianmin Xue, Yingze Zhang, S. Duncan (2015)
Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary FibrosisPLoS ONE, 10
Raghu (2011)
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and managementAm J Respir Crit Care Med, 183
G. Raghu, D. Lynch, J. Godwin, R. Webb, T. Colby, K. Leslie, J. Behr, K. Brown, J. Egan, K. Flaherty, F. Martinez, A. Wells, L. Shao, Huafeng Zhou, P. Pedersen, R. Sood, A. Montgomery, T. O'Riordan (2014)
Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial.The Lancet. Respiratory medicine, 2 4
D. Kim, H. Collard, T. King (2006)
Classification and natural history of the idiopathic interstitial pneumonias.Proceedings of the American Thoracic Society, 3 4
P. Noble, C. Albera, W. Bradford, U. Costabel, M. Glassberg, D. Kardatzke, T. King, L. Lancaster, S. Sahn, J. Szwarcberg, D. Valeyre, R. Bois (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 377
R. Tobin, C. Pope, C. Pellegrini, M. Emond, J. Sillery, G. Raghu (1998)
Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine, 158 6
Ross, C. Klingsberg, Steven, E. Mutsaers, Joseph, A. Lasky (2009)
INVITED REVIEW SERIES: PULMONARY FIBROSIS
I. Gaunaurd, O. Gómez-Marín, C. Ramos, C. Sol, M. Cohen, L. Cahalin, D. Cardenas, R. Jackson (2014)
Physical Activity and Quality of Life Improvements of Patients With Idiopathic Pulmonary Fibrosis Completing a Pulmonary Rehabilitation ProgramRespiratory Care, 59
D. Lederer, W. Bradford, E. Fagan, I. Glaspole, M. Glassberg, Kenneth Glasscock, D. Kardatzke, T. King, L. Lancaster, S. Nathan, C. Pereira, S. Sahn, J. Swigris, P. Noble (2015)
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.Chest, 148 1
D. Chauhan, Ashwin Karanam, A. Merlo, PA Bozzay, M. Zucker, H. Seethamraju, N. Shariati, Mark Russo, Mark Russo (2016)
Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 35 5
I. Lasithiotaki, K. Antoniou, Virginia-Maria Vlahava, K. Karagiannis, D. Spandidos, N. Siafakas, G. Sourvinos (2011)
Detection of Herpes Simplex Virus Type-1 in Patients with Fibrotic Lung DiseasesPLoS ONE, 6
Y. Miyake, S. Sasaki, T. Yokoyama, K. Chida, A. Azuma, T. Suda, S. Kudoh, N. Sakamoto, K. Okamoto, G. Kobashi, M. Washio, Y. Inaba, Heizo Tanaka (2005)
Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan.The Annals of occupational hygiene, 49 3
Klingsberg (2010)
Current clinical trials for the treatment of idiopathic pulmonary fibrosisRespirology, 15
Joyce Lee, H. Collard, K. Anstrom, F. Martinez, I. Noth, R. Roberts, E. Yow, G. Raghu (2013)
Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.The Lancet. Respiratory medicine, 1 5
L. Richeldi, R. Bois, G. Raghu, A. Azuma, K. Brown, U. Costabel, V. Cottin, K. Flaherty, D. Hansell, Y. Inoue, D. Kim, M. Kolb, A. Nicholson, P. Noble, M. Selman, H. Taniguchi, M. Brun, F. Maulf, M. Girard, S. Stowasser, R. Schlenker‐Herceg, B. Disse, H. Collard (2014)
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.The New England journal of medicine, 370 22
Y. Arase, F. Suzuki, Yoshiyuki Suzuki, N. Akuta, M. Kobayashi, Y. Kawamura, Hiromi Yatsuji, H. Sezaki, T. Hosaka, M. Hirakawa, Satoshi Saito, K. Ikeda, H. Kumada (2008)
Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis.World journal of gastroenterology, 14 38
P. Noble, C. Albera, W. Bradford, U. Costabel, R. Bois, E. Fagan, R. Fishman, I. Glaspole, M. Glassberg, L. Lancaster, D. Lederer, J. Leff, S. Nathan, C. Pereira, J. Swigris, D. Valeyre, T. King (2016)
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsThe European Respiratory Journal, 47
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive and irreversible fibrosis of lung parenchyma that reduces lung function. This rare, incurable disease often is mistaken for an inflammatory condition. IPF typically manifests in older men and is associated with a history of smoking. Disease progression is rapid, with a 5-year survival rate of 20%. Treatment options include lung transplantation and medical therapies to reduce the steady decline in lung function. This article reviews the epidemiology, pathophysiology, presentation, diagnosis, and management of IPF.
Journal of the American Academy of PAs – Wolters Kluwer Health
Published: Sep 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.